Barclays Downgrades Janux Therapeutics to Underweight, Lowers Price Target to $14
Benzinga Newsdesk 6 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout downgrades Janux Therapeutics (NASDAQ:JANX) from Overweight to Underweight and lowers the price target from $29 to $14.
Barclays analyst Etzer Darout downgrades Janux Therapeutics (NASDAQ:JANX) from Overweight to Underweight and lowers the price target from $29 to $14.